%0 Journal Article
%A Poveda, A.
%A Martinez, V.
%A Serrano, C.
%A Sevilla, I.
%A Lecumberri, M. J.
%A de Beveridge, R. D.
%A Estival, A.
%A Vicente, D.
%A Rubio, J.
%A Martin-Broto, J.
%T SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016)
%D 2016
%@ 1699-048X
%U http://hdl.handle.net/10668/18651
%X Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract, and this disease has served as a paradigmatic model for successful rational development of targeted therapies. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. The Spanish Society of Medical Oncology (SEOM) guidelines provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.
%K GIST
%K Imatinib
%K Sunitinib
%K Regorafenib
%K Stromal tumors
%K Adjuvant imatinib
%K Randomized-trial
%K Phase-iii
%K Follow-up
%K Kinase
%K Risk
%K Multicenter
%K Sensitivity
%K Recurrence
%~